Are there any FDA‑approved medications for prolonged grief disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

FDA-Approved Medications for Prolonged Grief Disorder

There are currently no FDA-approved medications specifically for prolonged grief disorder (PGD). The FDA has not granted approval for any pharmacological agent to treat this condition, which was only recently codified as a distinct diagnostic entity in ICD-11 and DSM-5-TR 1, 2.

Evidence-Based Treatment Approach

First-Line Treatment: Psychotherapy

Cognitive-behavioral therapy (CBT) specifically targeting grief should be the primary treatment for PGD, as it demonstrates the most robust evidence for efficacy 1, 2, 3.

  • Prolonged grief-specific CBT (PG-CBT) shows large effect sizes (Cohen's d=1.61 in treatment completers, d=1.32 in intent-to-treat analysis) with acceptable dropout rates (21% in one trial) 4
  • Treatment typically consists of 20-25 individual sessions over approximately 6 months 4, 5
  • Third-wave CBT demonstrates statistically significant reductions in grief symptoms (SMD=-1.00; 95% CI=-1.41, -0.58) and is particularly effective for secondary outcomes including depression (SMD=-0.60), PTSD (SMD=-0.99), and anxiety (SMD=-1.44) 2

Alternative Psychotherapy Options

When PG-CBT is unavailable, consider these alternatives in descending order of efficacy 2:

  • Behavioral therapy (SMD=-1.05; 95% CI=-1.71, -0.38)
  • Family therapy (SMD=-0.87; 95% CI=-1.59, -0.16)
  • Psychodynamic therapy (SMD=-0.88; 95% CI=-1.67, -0.10)
  • Standard cognitive therapy (SMD=-0.84; 95% CI=-1.57, -0.12)

Role of Pharmacotherapy

Antidepressant medication may serve as a useful adjunctive treatment to grief-specific psychotherapy, particularly for:

  • Facilitating completion of grief therapy 1
  • Reducing bereavement-related depression when present as a comorbid condition 1
  • Managing comorbid symptoms (patients with PGD average 2.5 comorbid diagnoses) 4

SSRIs, particularly sertraline, should be considered when pharmacotherapy is indicated, as they have demonstrated safety in patients with psychological distress and minimal cardiovascular toxicity 6, 7.

Critical Clinical Considerations

When to Treat vs. When to Observe

Do not deploy grief therapy as a universal intervention for all bereaved individuals 1, 3:

  • Grief therapy is efficacious only when targeted to individuals with persistent and elevated levels of distress 1
  • Universal grief interventions show minimal to no benefits for adults or children 1
  • Reserve treatment for those meeting diagnostic criteria for PGD (severe, persistent, and disabling grief) 1, 2

Common Pitfalls to Avoid

  • Avoid prescribing medication as monotherapy without concurrent grief-specific psychotherapy, as there is no evidence supporting pharmacotherapy alone for PGD 1, 2
  • Do not use benzodiazepines for anxiety management in elderly patients with grief, as they increase fall risk and anticholinergic burden 7
  • Avoid tricyclic antidepressants due to cardiovascular toxicity including QTc prolongation and orthostatic hypotension 6, 7

Monitoring and Follow-up

When using adjunctive antidepressants 6:

  • Allow up to 6 weeks for SSRI effects to manifest
  • Monitor blood pressure in patients taking sertraline
  • Screen for drug interactions, particularly with cardiovascular medications
  • Assess for treatment-emergent suicidal ideation, especially in younger patients

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.